Why the GLP-1 Boom Demands a New Aesthetic Playbook

Following two recent industry events this month at Octane’s Aesthetics Tech Forum and the J.P. Morgan Healthcare Conference, it was hard to miss how central GLP-1s have become to nearly every healthcare conversation. Topics ranged from manufacturing capacity and access to new formulations, and what “chronic care” looks like at population scale.

As we prepare to attend IMCAS World Congress this week, one storyline feels especially clear: GLP-1s are central to the obesity care landscape, whilst in aesthetics they are creating new demand for regenerative approaches that address soft-tissue changes associated with rapid weight loss. What is most compelling is the “knock-on” effect within the aesthetics practice as patients see unexpected skin laxity and facial volume changes that were typically attributed to aging and sun damage but now importantly after significant weight loss. Initially described on social media as “Ozempic face,” the underlying dynamic is familiar: less subcutaneous soft-tissue support combined with adverse changes in the skin composition can reveal laxity, deepen folds, and shift facial contours ¹, resulting in a change in facial structure in ways that can affect the patient’s confidence and quality of life.

In a McKinsey’s survey of 174 aesthetics providers, they found that most GLP-1 patients seeking facial aesthetic treatments were new to the category, and that skin laxity and facial volume loss are among the most common concerns reported in practice ².

Aesthetic manufacturers have responded, from non-invasive approaches including bio-stimulatory/HA injectables and energy-based devices, to a renewed interest in fat grafting and surgical options that depend on the patient’s goals and the degree of change required ³.

This gives rise to a few takeaways:

This isn’t “aesthetics vs. health.” GLP-1s deliver meaningful cardiometabolic benefits for many patients, and the future pipeline, including new oral options suggests the category’s impact will only broaden.

Downstream effects are real and addressable. If we are serious about patient outcomes, we should be serious about the full patient journey, including appearance-related concerns that can emerge after medication-driven weight loss.

Regeneration matters. As this new patient cohort enters aesthetics, approaches that improve the structure and biology of tissue may become increasingly important alongside traditional volumization tools.

Having worked in the field for over 10 years, my understanding is that treating structure results in better outcomes than treating symptoms alone. That is why I am focused on regenerative aesthetics where the opportunity is to find solutions that aim to restore or support tissue “architecture,” and not just replace volume.

At Conexeu Sciences, we are developing a thermosensitive extracellular matrix (ECM) scaffold, initially as an injectable, that is designed to provide the temporary structural support the body needs while it remodels tissue. We are excited by the science, and it is our belief that solutions addressing tissue architecture and regeneration (vs. volume replacement alone) will undoubtedly become an important part of how the field helps patients navigate medication-driven weight loss.

I am curious to know how others are thinking about this: how has the patient’s narrative shifted your focus on GLP-1-driven aesthetic needs in your clinic, portfolio, or product roadmap? What do you think will define the next wave of “regenerative aesthetics”?

Sources:

Additional Resources:

‍

Why the GLP-1 Boom Demands a New Aesthetic Playbook

News and Media

Contact Us